{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:26:50Z","timestamp":1792596410508,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05143-y","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T14:06:45Z","timestamp":1653314805000},"page":"1665-1679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7948-5394","authenticated-orcid":false,"given":"Tatjana","family":"Zeki\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4123-9937","authenticated-orcid":false,"given":"Mirjana Stani\u0107","family":"Beni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-6800","authenticated-orcid":false,"given":"Mislav","family":"Radi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"5143_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.mayocp.2013.09.016","volume":"89","author":"MD Leise","year":"2014","unstructured":"Leise MD, Poterucha JJ, Talwalkar JA (2014) Drug-induced liver injury. Mayo Clin Proc 89:95\u2013106. https:\/\/doi.org\/10.1016\/j.mayocp.2013.09.016","journal-title":"Mayo Clin Proc"},{"key":"5143_CR2","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ajg.2014.131","volume":"109","author":"NP Chalasani","year":"2014","unstructured":"Chalasani NP, Hayashi PH, Bonkovsky HL et al (2014) ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 109:950\u2013966. https:\/\/doi.org\/10.1038\/ajg.2014.131","journal-title":"Am J Gastroenterol"},{"key":"5143_CR3","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Aithal GP, Bj\u00f6rnsson ES et al (2019) EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 70:1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"5143_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","volume":"7","author":"GP Aithal","year":"2011","unstructured":"Aithal GP (2011) Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol 7:139\u2013150. https:\/\/doi.org\/10.1038\/nrrheum.2010.214","journal-title":"Nat Rev Rheumatol"},{"key":"5143_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00296-018-4021-5","volume":"38","author":"B Radovanovi\u0107-Dini\u0107","year":"2018","unstructured":"Radovanovi\u0107-Dini\u0107 B, Te\u0161i\u0107-Rajkovi\u0107 S, Zivkovic V, Grgov S (2018) Clinical connection between rheumatoid arthritis and liver damage. Rheumatol Int 38:715\u2013724","journal-title":"Rheumatol Int"},{"key":"5143_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejim.2015.12.017","volume":"28","author":"A Licata","year":"2016","unstructured":"Licata A (2016) Adverse drug reactions and organ damage: the liver. Eur J Intern Med 28:9\u201316. https:\/\/doi.org\/10.1016\/j.ejim.2015.12.017","journal-title":"Eur J Intern Med"},{"key":"5143_CR7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/bcp.12885","volume":"81","author":"I Metushi","year":"2016","unstructured":"Metushi I, Uetrecht J, Phillips E (2016) Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol 81:1030\u20131036. https:\/\/doi.org\/10.1111\/bcp.12885","journal-title":"Br J Clin Pharmacol"},{"key":"5143_CR8","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1007\/s12325-021-01669-y","volume":"38","author":"M Cataldi","year":"2021","unstructured":"Cataldi M, Citro V, Resnati C et al (2021) New avenues for treatment and prevention of drug-induced steatosis and steatohepatitis: much more than antioxidants. Adv Ther 38:2094\u20132113. https:\/\/doi.org\/10.1007\/s12325-021-01669-y","journal-title":"Adv Ther"},{"key":"5143_CR9","doi-asserted-by":"publisher","first-page":"152840","DOI":"10.1016\/j.tox.2021.152840","volume":"458","author":"D Ezhilarasan","year":"2021","unstructured":"Ezhilarasan D (2021) Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms. Toxicology 458:152840. https:\/\/doi.org\/10.1016\/j.tox.2021.152840","journal-title":"Toxicology"},{"key":"5143_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40264-020-00938-z","volume":"43","author":"V Veeravalli","year":"2020","unstructured":"Veeravalli V, Dash RP, Thomas JA et al (2020) Critical assessment of pharmacokinetic drug-drug interaction potential of tofacitinib, baricitinib and upadacitinib, the three approved janus kinase inhibitors for rheumatoid arthritis treatment. Drug Saf 43:711\u2013725","journal-title":"Drug Saf"},{"key":"5143_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fphar.2019.00855","volume":"10","author":"X Qiao","year":"2019","unstructured":"Qiao X, Zhou Z-C, Niu R et al (2019) Hydroxychloroquine improves obesity-associated insulin resistance and hepatic steatosis by regulating lipid metabolism. Front Pharmacol 10:855. https:\/\/doi.org\/10.3389\/fphar.2019.00855","journal-title":"Front Pharmacol"},{"key":"5143_CR12","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"5143_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"5143_CR14","doi-asserted-by":"publisher","first-page":"789","DOI":"10.5604\/16652681.1171749","volume":"14","author":"SK Satapathy","year":"2015","unstructured":"Satapathy SK, Kuwajima V, Nadelson J et al (2015) Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol 14:789\u2013806. https:\/\/doi.org\/10.5604\/16652681.1171749","journal-title":"Ann Hepatol"},{"key":"5143_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cld.2013.07.004","volume":"17","author":"X Zhang","year":"2013","unstructured":"Zhang X, Ouyang J, Thung SN (2013) Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis 17:547\u2013564. https:\/\/doi.org\/10.1016\/j.cld.2013.07.004","journal-title":"Clin Liver Dis"},{"key":"5143_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/jcp.2008.058248","volume":"62","author":"R Ramachandran","year":"2009","unstructured":"Ramachandran R, Kakar S (2009) Histological patterns in drug-induced liver disease. J Clin Pathol 62:481\u2013492. https:\/\/doi.org\/10.1136\/jcp.2008.058248","journal-title":"J Clin Pathol"},{"key":"5143_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203084","volume":"13","author":"S Mori","year":"2018","unstructured":"Mori S, Arima N, Ito M et al (2018) Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS ONE 13:e0203084. https:\/\/doi.org\/10.1371\/journal.pone.0203084","journal-title":"PLoS ONE"},{"key":"5143_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00535-012-0704-y","volume":"48","author":"M Yoneda","year":"2013","unstructured":"Yoneda M, Imajo K, Eguchi Y et al (2013) Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol 48:1051\u20131060. https:\/\/doi.org\/10.1007\/s00535-012-0704-y","journal-title":"J Gastroenterol"},{"key":"5143_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.aohep.2019.01.011","volume":"18","author":"DS Garc\u00eda","year":"2019","unstructured":"Garc\u00eda DS, Saturansky EI, Poncino D et al (2019) Hepatic toxicity by methotrexate with weekly single doses associated with folic acid in rheumatoid and psoriatic arthritis. What is its real frequency? Ann Hepatol 18:765\u2013769","journal-title":"Ann Hepatol"},{"key":"5143_CR20","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1007\/s10067-021-05678-8","volume":"40","author":"P Bafna","year":"2021","unstructured":"Bafna P, Sahoo RR, Hazarika K et al (2021) Prevalence of liver fibrosis by fibroscan in patients on long-term methotrexate therapy for rheumatoid arthritis. Clin Rheumatol 40:3605\u20133613. https:\/\/doi.org\/10.1007\/s10067-021-05678-8","journal-title":"Clin Rheumatol"},{"key":"5143_CR21","doi-asserted-by":"publisher","first-page":"003","DOI":"10.1055\/s-2001-12925","volume":"21","author":"EM Brunt","year":"2001","unstructured":"Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21:003\u2013016","journal-title":"Semin Liver Dis"},{"key":"5143_CR22","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313\u20131321","journal-title":"Hepatology"},{"key":"5143_CR23","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","volume":"13","author":"S Singh","year":"2015","unstructured":"Singh S, Allen AM, Wang Z et al (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643-654.e9. https:\/\/doi.org\/10.1016\/j.cgh.2014.04.014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5143_CR24","first-page":"862","volume":"37","author":"A Doria","year":"2019","unstructured":"Doria A, Zavaglia D (2019) Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol 37:862\u2013871","journal-title":"Clin Exp Rheumatol"},{"key":"5143_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/1756-185X.13442","volume":"22","author":"R Lertnawapan","year":"2019","unstructured":"Lertnawapan R, Chonprasertsuk S, Siramolpiwat S (2019) Association between cumulative methotrexate dose, non-invasive scoring system and hepatic fibrosis detected by fibroscan in rheumatoid arthritis patients receiving methotrexate. Int J Rheum Dis 22:214\u2013221. https:\/\/doi.org\/10.1111\/1756-185X.13442","journal-title":"Int J Rheum Dis"},{"key":"5143_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkaa020","author":"S Mori","year":"2020","unstructured":"Mori S, Arima N, Ito M et al (2020) Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. Rheumatol Adv Practi. https:\/\/doi.org\/10.1093\/rap\/rkaa020","journal-title":"Rheumatol Adv Practi"},{"key":"5143_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.112","author":"MV Chakravarthy","year":"2020","unstructured":"Chakravarthy MV, Neuschwander-Tetri BA (2020) The metabolic basis of non-alcoholic steatohepatitis. Pediatr Endocrinol Diabetes Metab. https:\/\/doi.org\/10.1002\/edm2.112","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"5143_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","volume":"155","author":"A Mansouri","year":"2018","unstructured":"Mansouri A, Gattolliat C-H, Asselah T (2018) Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology 155:629\u2013647. https:\/\/doi.org\/10.1053\/j.gastro.2018.06.083","journal-title":"Gastroenterology"},{"key":"5143_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00335-014-9521-3","volume":"25","author":"JD Riordan","year":"2014","unstructured":"Riordan JD, Nadeau JH (2014) Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 25:473\u2013486. https:\/\/doi.org\/10.1007\/s00335-014-9521-3","journal-title":"Mamm Genome"},{"key":"5143_CR30","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcmgh.2018.07.004","volume":"6","author":"O Pickett-Blakely","year":"2018","unstructured":"Pickett-Blakely O, Young K, Carr RM (2018) Micronutrients in nonalcoholic fatty liver disease pathogenesis. Cell Mol Gastroenterol Hepatol 6:451\u2013462","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"5143_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cld.765","volume":"13","author":"JG Labadie","year":"2019","unstructured":"Labadie JG, Jain M (2019) Noninvasive tests to monitor methotrexate-induced liver injury. Clin Liver Dis 13:67\u201371. https:\/\/doi.org\/10.1002\/cld.765","journal-title":"Clin Liver Dis"},{"key":"5143_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"A Berzigotti","year":"2021","unstructured":"Berzigotti A, Tsochatzis E, Boursier J et al (2021) EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis\u20142021 update. J Hepatol 75:659\u2013689. https:\/\/doi.org\/10.1016\/j.jhep.2021.05.025","journal-title":"J Hepatol"},{"key":"5143_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","volume":"39","author":"P Emery","year":"2000","unstructured":"Emery P, Breedveld FC, Lemmel EM et al (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 39:655\u2013665. https:\/\/doi.org\/10.1093\/rheumatology\/39.6.655","journal-title":"Rheumatology"},{"key":"5143_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/ard.2008.101378","volume":"69","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Beukelman T, Onofrei A et al (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide. Ann Rheum Dis 69:43\u201347. https:\/\/doi.org\/10.1136\/ard.2008.101378","journal-title":"Ann Rheum Dis"},{"key":"5143_CR35","first-page":"1029","volume":"35","author":"A Rouhi","year":"2017","unstructured":"Rouhi A, Hazlewood G, Shaheen A-A et al (2017) Prevalence and risk factors for liver fibrosis detected by transient elastography or shear wave elastography in inflammatory arthritis: a systematic review. Clin Exp Rheumatol 35:1029\u20131036","journal-title":"Clin Exp Rheumatol"},{"key":"5143_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tox.2018.02.003","volume":"396\u2013397","author":"J Xuan","year":"2018","unstructured":"Xuan J, Ren Z, Qing T et al (2018) Mitochondrial dysfunction induced by leflunomide and its active metabolite. Toxicology 396\u2013397:33\u201345. https:\/\/doi.org\/10.1016\/j.tox.2018.02.003","journal-title":"Toxicology"},{"key":"5143_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3899\/jrheum.120922","volume":"40","author":"P Bird","year":"2013","unstructured":"Bird P, Griffiths H, Tymms K et al (2013) The smile study\u2014safety of methotrexate in combination with leflunomide in rheumatoid arthritis. J Rheumatol 40:228\u2013235. https:\/\/doi.org\/10.3899\/jrheum.120922","journal-title":"J Rheumatol"},{"key":"5143_CR38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.amjmed.2004.02.032","volume":"117","author":"S Suissa","year":"2004","unstructured":"Suissa S, Ernst P, Hudson M et al (2004) Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 117:87\u201392. https:\/\/doi.org\/10.1016\/j.amjmed.2004.02.032","journal-title":"Am J Med"},{"key":"5143_CR39","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40264-015-0366-9","volume":"39","author":"JB French","year":"2016","unstructured":"French JB, Bonacini M, Ghabril M et al (2016) Hepatotoxicity associated with the use of anti-TNF-\u03b1 agents. Drug Saf 39:199\u2013208. https:\/\/doi.org\/10.1007\/s40264-015-0366-9","journal-title":"Drug Saf"},{"key":"5143_CR40","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/ard.2009.112136","volume":"69","author":"J Sokolove","year":"2010","unstructured":"Sokolove J, Strand V, Greenberg JD et al (2010) Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 69:1612\u20131617. https:\/\/doi.org\/10.1136\/ard.2009.112136","journal-title":"Ann Rheum Dis"},{"key":"5143_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13075-019-2028-2","volume":"21","author":"MD Bandt","year":"2019","unstructured":"Bandt MD (2019) Anti-TNF-alpha-induced lupus. Arthritis Res Ther 21:235","journal-title":"Arthritis Res Ther"},{"key":"5143_CR42","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3390\/ijms19082199","volume":"19","author":"L Lopetuso","year":"2018","unstructured":"Lopetuso L, Mocci G, Marzo M et al (2018) Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver. Int J Mol Sci 19:2199. https:\/\/doi.org\/10.3390\/ijms19082199","journal-title":"Int J Mol Sci"},{"key":"5143_CR43","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/hep4.1465","volume":"4","author":"P Shah","year":"2020","unstructured":"Shah P, Sundaram V, Bj\u00f6rnsson E (2020) Biologic and checkpoint inhibitor-induced liver injury: a systematic literature review. Hepatol Commun 4:172\u2013184. https:\/\/doi.org\/10.1002\/hep4.1465","journal-title":"Hepatol Commun"},{"key":"5143_CR44","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.cgh.2014.07.062","volume":"13","author":"ES Bj\u00f6rnsson","year":"2015","unstructured":"Bj\u00f6rnsson ES, Gunnarsson BI, Gr\u00f6ndal G et al (2015) Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol 13:602\u2013608","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5143_CR45","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41419-020-2411-6","volume":"11","author":"F Wandrer","year":"2020","unstructured":"Wandrer F, Liebig S, Marhenke S et al (2020) TNF-receptor-one inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis 11:212. https:\/\/doi.org\/10.1038\/s41419-020-2411-6","journal-title":"Cell Death Dis"},{"key":"5143_CR46","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s42255-021-00470-z","volume":"3","author":"JK Sethi","year":"2021","unstructured":"Sethi JK, Hotamisligil GS (2021) Metabolic messengers: tumour necrosis factor. Nat Metab 3:1302\u20131312. https:\/\/doi.org\/10.1038\/s42255-021-00470-z","journal-title":"Nat Metab"},{"key":"5143_CR47","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (2017). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548243"},{"key":"5143_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","volume":"29","author":"A Ogata","year":"2019","unstructured":"Ogata A, Kato Y, Higa S, Yoshizaki K (2019) IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol 29:258\u2013267. https:\/\/doi.org\/10.1080\/14397595.2018.1546357","journal-title":"Mod Rheumatol"},{"key":"5143_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:69\u201374. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203523","journal-title":"Ann Rheum Dis"},{"key":"5143_CR50","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/art.40176","volume":"69","author":"MC Genovese","year":"2017","unstructured":"Genovese MC, Kremer JM, van Vollenhoven RF et al (2017) Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis. Arthritis Rheumatol 69:1751\u20131761. https:\/\/doi.org\/10.1002\/art.40176","journal-title":"Arthritis Rheumatol"},{"key":"5143_CR51","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R et al (2017) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis 76:840\u2013847. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210310","journal-title":"Ann Rheum Dis"},{"key":"5143_CR52","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","volume":"64","author":"D Schmidt-Arras","year":"2016","unstructured":"Schmidt-Arras D, Rose-John S (2016) IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol 64:1403\u20131415","journal-title":"J Hepatol"},{"key":"5143_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00877","author":"M-F Xia","year":"2019","unstructured":"Xia M-F, Bian H, Gao X (2019) NAFLD and diabetes two sides of the same coin? Rationale for gene-based personalized NAFLD treatment. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2019.00877","journal-title":"Front Pharmacol"},{"key":"5143_CR54","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.3390\/ijms21176290","volume":"21","author":"O Patsalos","year":"2020","unstructured":"Patsalos O, Dalton B, Himmerich H (2020) Effects of IL-6 signaling pathway inhibition on weight and BMI: a systematic review and meta-analysis. Int J Mol Sci 21:6290. https:\/\/doi.org\/10.3390\/ijms21176290","journal-title":"Int J Mol Sci"},{"key":"5143_CR55","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13102-022-00397-2","volume":"14","author":"S Docherty","year":"2022","unstructured":"Docherty S, Harley R, McAuley JJ et al (2022) The effect of exercise on cytokines: implications for musculoskeletal health: a narrative review. BMC Sports Sci Med Rehabil 14:5. https:\/\/doi.org\/10.1186\/s13102-022-00397-2","journal-title":"BMC Sports Sci Med Rehabil"},{"key":"5143_CR56","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"5143_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3899\/jrheum.161161","volume":"45","author":"EC Keystone","year":"2018","unstructured":"Keystone EC, Genovese MC, Schlichting DE et al (2018) Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol 45:14\u201321. https:\/\/doi.org\/10.3899\/jrheum.161161","journal-title":"J Rheumatol"},{"key":"5143_CR58","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508\u2013519","journal-title":"N Engl J Med"},{"key":"5143_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367:495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071","journal-title":"N Engl J Med"},{"issue":"10","key":"5143_CR60","first-page":"1548","volume":"8","author":"RB Mueller","year":"2019","unstructured":"Mueller RB, Hasler C, Popp F et al (2019) Effectiveness tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med Res 8(10):1548","journal-title":"J Clin Med Res"},{"key":"5143_CR61","first-page":"485","volume":"37","author":"R Caporali","year":"2019","unstructured":"Caporali R, Zavaglia D (2019) Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 37:485\u2013495","journal-title":"Clin Exp Rheumatol"},{"key":"5143_CR62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/OARRR.S322086","volume":"13","author":"I Bertoldi","year":"2021","unstructured":"Bertoldi I, Caporali R (2021) Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis. Open Access Rheumatol 13:221\u2013237. https:\/\/doi.org\/10.2147\/OARRR.S322086","journal-title":"Open Access Rheumatol"},{"key":"5143_CR63","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","volume":"60","author":"J Fitton","year":"2021","unstructured":"Fitton J, Melville AR, Emery P et al (2021) Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology 60:4048\u20134054. https:\/\/doi.org\/10.1093\/rheumatology\/keaa858","journal-title":"Rheumatology"},{"key":"5143_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390","volume":"18","author":"Y Jamilloux","year":"2019","unstructured":"Jamilloux Y, Jammal TE, Vuitton L et al (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 18:102390. https:\/\/doi.org\/10.1016\/j.autrev.2019.102390","journal-title":"Autoimmun Rev"},{"key":"5143_CR65","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/acr.24007","volume":"72","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Takeuchi T, Schiff M et al (2020) Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. Arthritis Care Res 72:1112\u20131121. https:\/\/doi.org\/10.1002\/acr.24007","journal-title":"Arthritis Care Res"},{"key":"5143_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2020.9154","volume":"20","author":"M Shao","year":"2020","unstructured":"Shao M, Ye Z, Qin Y, Wu T (2020) Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (review). Exp Ther Med 20:1\u20131. https:\/\/doi.org\/10.3892\/etm.2020.9154","journal-title":"Exp Ther Med"},{"issue":"2","key":"5143_CR67","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/rheumatology\/keaa895","volume":"60","author":"B Clarke","year":"2021","unstructured":"Clarke B, Yates M, Adas M et al (2021) The safety of JAK-1 inhibitors. Rheumatol 60(2):24\u201330","journal-title":"Rheumatol"},{"key":"5143_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.06.010","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao J, Qi Y-F, Yu Y-R (2021) STAT3: a key regulator in liver fibrosis. Ann Hepatol 21:100224","journal-title":"Ann Hepatol"},{"key":"5143_CR69","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","volume":"175","author":"M Grohmann","year":"2018","unstructured":"Grohmann M, Wiede F, Dodd GT et al (2018) Obesity drives STAT-one-dependent NASH and STAT-three-dependent HCC. Cell 175:1289-1306.e20","journal-title":"Cell"},{"key":"5143_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ (2018) The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 10:117\u2013127. https:\/\/doi.org\/10.1177\/1759720X18776224","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5143_CR71","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jcph.1414","volume":"59","author":"S Trueman","year":"2019","unstructured":"Trueman S, Mohamed MF, Feng T et al (2019) Characterization of the effect of hepatic impairment on upadacitinib pharmacokinetics. J Clin Pharmacol 59:1188\u20131194. https:\/\/doi.org\/10.1002\/jcph.1414","journal-title":"J Clin Pharmacol"},{"key":"5143_CR72","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3899\/jrheum.120573","volume":"39","author":"EC Keystone","year":"2012","unstructured":"Keystone EC, Cohen SB, Emery P et al (2012) Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to one or more tumor necrosis factor inhibitors: five-year data from the reflex study. J Rheumatol 39:2238\u20132246. https:\/\/doi.org\/10.3899\/jrheum.120573","journal-title":"J Rheumatol"},{"key":"5143_CR73","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","volume":"72","author":"RF van Vollenhoven","year":"2013","unstructured":"van Vollenhoven RF, Emery P, Bingham CO et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496\u20131502","journal-title":"Ann Rheum Dis"},{"key":"5143_CR74","unstructured":"LiverTox: Clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (2012). Rituximab. [Updated 2018 Jun 18]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548249\/"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05143-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05143-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T06:04:50Z","timestamp":1662098690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05143-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":74,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["5143"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05143-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"12 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This narrative review is written in compliance with ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}